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The emergence of multidrug-resistant pathogens renders antibiotics ineffective in the treatment of lung
infections in patients with cystic fibrosis (CF). Designed antimicrobial peptides (DAPs) are laboratory-
synthesized peptide antibiotics that demonstrate a wide spectrum of antibacterial activity. Optimal conditions
for susceptibility testing of these peptides have not yet been established. Medium composition is clearly a major
factor influencing the results and reproducibilities of susceptibility tests. Using time-kill assays, we tested the
effects of different media and buffers on the bactericidal activities of the peptides D2A21 and D4E1 on
Staphylococcus aureus ATCC 29213 and Pseudomonas aeruginosa ATCC 27853. Each peptide at 1 and 5 mM was
incubated with bacteria in the different media and buffers. Both peptides were most active in Tris-HCl buffer
against S. aureus and P. aeruginosa. Among the more complex media tested, modified RPMI medium was the
medium in which the peptides demonstrated the highest activity, while it supported the growth of the bacteria.
The broth microdilution technique was used to test the activities of D2A21 and D4E1 in modified RPMI
medium against multidrug-resistant pathogens from patients with CF. The MICs of DAPs for methicillin-
resistant S. aureus ranged from 0.25 to 4 mg/ml, those for multidrug-resistant P. aeruginosa ranged from 0.125
to 4 mg/ml, those for Stenotrophomonas maltophilia ranged from 0.5 to 32 mg/ml, and those for Burkholderia
cepacia ranged from 32 to >64 mg/ml. When the activity of peptide D2A21 was compared with that of the
tracheal antimicrobial peptide (TAP), D2A21 had greater potency than TAP against P. aeruginosa. In addition,
no difference in the MICs of D2A21 was seen when it was tested in nutrient broth supplemented with NaCl at
different concentrations. Thus, DAPs are a class of salt-insensitive antibiotics potentially useful in the treat-
ment of CF patients harboring multidrug-resistant P. aeruginosa.
The emergence of multidrug-resistant pathogens increas-
ingly renders antibiotics ineffective in the treatment of lung
infections due to cystic fibrosis (CF), the most common fatal
genetic disease in the United States. The past few years have
brought dramatic advances in our knowledge of the molecular
and cellular basis of CF lung disease (3, 8, 16). Several hypoth-
eses have been proposed to explain the development of bron-
chitis due to an unusual mucoid phenotype of Pseudomonas
aeruginosa based on the characteristic physiologic abnormality,
the defective transport of chloride ions across the apical mem-
brane of the airway epithelia (4, 14, 18, 19, 23). It has been
proposed that the lack of Cl2 secretion promotes airway drying
and mucus plugging, thus predisposing the airways to chronic
colonization. Why mucus plugging should promote airway col-
onization predominantly with P. aeruginosa and not with other
bacterial lung pathogens such as Streptococcus pneumoniae, as
seen in non-CF patients, is not understood. An attempt has
been made to prove a link between Cl2 secretion and infection
by attributing airway infection to altered antimicrobial activity
of salt-sensitive, epithelial cell-derived peptides in patients
with CF (23). The investigators proposed that the defect in the
CF gene product elevates NaCl levels in airway surface liquid
and thereby inactivates antimicrobial molecules. Recently, an
antimicrobial peptide, human b-defensin-1 (hBD-1), has been
identified (6). It is expressed in human airway epithelial cells
and shows broad-spectrum antimicrobial activity against gram-
negative organisms. Furthermore, its antimicrobial activity
may be salt dependent in airway surface fluids, although the
point is controversial. The ion composition of airway surface
fluid in the airways of healthy people and patients with CF is
not yet defined (5, 9, 10).
The discovery of antibacterial epithelium-derived peptides
suggests avenues for the development of innovative therapies,
such as replacement of these peptides with salt-insensitive syn-
thetic peptides which would restore the sterile airway environ-
ment and halt or slow the airway disease in patients with CF.
We now report on the in vitro activities of designed anti-
microbial peptides (DAPs), laboratory-synthesized peptides
which are similar to the naturally occurring peptides such as
tracheal antimicrobial peptide (TAP) (11), defensins (2, 12),
and magainins (1). Unlike hBD-1, the antibacterial activities of
DAPs are salt insensitive.
(These data were presented in part at the 37th Interscience
Conference on Antimicrobial Agents and Chemotherapy, To-
ronto, Ontario, Canada, September 1997 [21].)
MATERIALS AND METHODS
Bacterial strains. The antibacterial activities of DAPs in different media
against American Type Culture Collection (ATCC) strains P. aeruginosa ATCC
27853 and Staphylococcus aureus ATCC 29213 were tested by time-kill assays.
Clinical isolates of methicillin-resistant S. aureus (MRSA; n 5 21), P. aeruginosa
(n 5 32), Stenotrophomonas maltophilia (n 5 16), and Burkholderia cepacia (n 5
10) were tested by the broth microdilution method.
DAPs. Seven DAPs (D2A21, D4E1, D2A22, D5C, D4E, D4B, and D5C1),
whose amino sequences are presented in Fig. 1, were screened for their activities
against S. aureus ATCC 29213 and P. aeruginosa ATCC 27853 in Mueller-Hinton
broth (MHB; Remel, Lenexa, Kans., at a 1 mM (2.8- to 5.6-mg/ml) concentration.
Stock solutions of the peptides were prepared by dissolving 1 mg of each
peptide in 1 ml or 500 ml of sterile distilled water. All subsequent dilutions were
made in test medium and were prepared fresh for each experiment.
Naturally occurring peptide. TAP (kindly provided by Scott Randall, Cystic
Fibrosis Center, University of North Carolina, Chapel Hill) was used in this study
and was prepared as described above for the DAPs.
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Media and buffers tested. The following media and buffers were tested for
their effects on the antimicrobial activities of the different peptides studied:
Trypticase soy broth (TSB; Becton Dickinson Microbiology Systems, Cock-
eysville, Md.), nutrient broth (NB; Becton Dickinson Microbiology Systems),
chemically defined RPMI 1640 medium (15) with 20 mM HEPES and without
sodium bicarbonate (catalog no. R7388; Sigma, St. Louis, Mo.), MHB, cation-
adjusted MHB supplemented with 20 to 25 mg of Ca21 per liter and 10 to 12.5
mg of Mg21 per liter (adjMHB) (17), 0.1 M Tris-HCl buffer (pH 7.2 and 8.4),
0.01 M phosphate-buffered saline (PBS), 0.1 M phosphate buffer and citrate-
phosphate buffer (pH 7.2 and 5.2), and unbuffered saline. All media and buffers
were tested for their osmolarity (Vapro Pressure Osmometer) and, if necessary,
were adjusted with NaCl to a physiologic osmolarity of 280 to 320 mosM. Fifty
and 90 mM NaCl were added to Tris-HCl (pH 7.2 and 8.4, respectively), 40 mM
NaCl was added to phosphate buffer, 50 and 70 mM were added to citrate-
phosphate buffer (pH 7.2 and 5.2, respectively), 5 mM NaCl was added to RPMI
1640 medium, and 120 mM NaCl was added to NB. Furthermore, the pH of
RPMI 1640 medium was standardized by adding an additional 10 mM HEPES
(modified RPMI).
The effect of osmolarity on the antibacterial activities of the peptides was
tested in NB (56 mosM; hypotonic), NB supplemented with 120 mM NaCl (290
mosM; isotonic), and NB supplemented with 170 mM NaCl (405 mosM; hyper-
tonic).
Preparation of inoculum. Bacteria from frozen suspensions were subcultured
onto sheep blood agar plates and were passaged twice prior to susceptibility
testing. The bacteria were then grown in TSB for 3 to 5 h (exponential-phase
cells) before adjusting their concentration to a 0.5 McFarland turbidity standard.
The adjusted bacterial cultures were diluted to approximately 105 CFU/ml. For
determination of the activities of the peptides in buffer, the bacteria were washed
and were then incubated with the peptides in appropriate buffer. To verify the
final inoculum size, the viable colonies in the inoculum were counted.
Killing curve method. To determine the effects of media and buffers on the
activities of the peptides, time-kill curve studies were performed as described in
the guidelines of the National Committee for Clinical Laboratory Standards (17).
Approximately 105 bacteria were incubated with 1 mM (4.3 mg/ml) and 5 mM
(21.5 mg/ml) D2A21 and 1 mM (2.8 mg/ml) and 5 mM (14 mg/ml) D4E1 in the
different media and buffers. Samples were removed at 0.5, 1, 2, and 4 h and the
numbers of colonies were determined. For this purpose the samples were serially
diluted in test tubes containing 4.5 ml of PBS to produce 10-fold dilutions. A
total of 100 ml was inoculated in duplicate onto sheep blood agar plates (media
base was Trypticase soy agar; Becton Dickinson Microbiology Systems) of each
dilution tube and was spread by using sterile bent glass rods. After overnight
incubation, the colonies were counted and average counts were determined. The
percentage of bacteria killed was determined by the following equation: 100 3
(log10 CFU per milliliter killed at end of incubation period with peptide)/(log10
CFU per milliliter at end of incubation period without peptide). We defined
killing of $99.9% of the final inoculum as 100% or total killing. All assays were
repeated at least once, with the difference between assays being #1 log10 CFU/
ml. The results presented in Fig. 2 and 3 are from a single representative
experiment.
MIC determination by broth microdilution technique. In preliminary experi-
ments the time-kill assay was compared to the broth microdilution technique.
Five strains each of MRSA and P. aeruginosa were tested in modified RPMI. No
differences in data between these two assays were seen. Thus, we used the broth
microdilution technique to test the activities of the peptides against pathogens
from patients with CF and compared their activities to the activity of the natu-
rally occurring peptide TAP. In addition, the osmolarity effect on the antibac-
terial activity of D2A21 was tested.
MICs were determined by the broth microdilution method described by the
National Committee for Clinical Laboratory Standards (17). Serial twofold di-
lutions of each peptide solution were prepared (final volume, 100 ml) in micro-
titer trays with appropriate medium. Each dilution series included control wells
containing bacteria without peptide. A total of 100 ml of the adjusted inoculum
(105 organisms) was added to each well, and then the trays were incubated at
35°C in ambient air overnight (18 to 24 h). The MIC of each peptide for each
isolate was read as the lowest concentration of peptide that inhibited visible
growth of the organism.
RESULTS
Screening of DAPs. Figure 2 demonstrates the bactericidal
activities of the seven tested peptides after 1 h of incubation.
D2A21, a linear, 23-amino-acid peptide, and D4E1, a linear,
17-amino-acid peptide, were the most active peptides against
both bacterial species and were extensively tested in this study.
Antibacterial effects of media and buffers on the activities of
D4E1 and D2A21. Modified RPMI was the medium in which
the peptides demonstrated the highest activity against both
S. aureus and P. aeruginosa (Table 1). S. aureus was killed
within 2 h by both D2A21 and D4E1 at 5 mM. P. aeruginosa was
more sensitive than S. aureus, with maximal killing by D2A21
at 1 and 5 mM occurring at 30 min and that by 5 mM D4E1
FIG. 1. Amino acid sequences of DAPs used in this study. The synthesis of
the peptides was done by 9-fluorenylmethoxycarbonyl chemistry.
FIG. 2. Bactericidal activities of DAPs against S. aureus ATCC 29213 and P. aeruginosa ATCC 27853. DAPs at a concentration of 1 mM were incubated with bacteria
in MHB for 1 h. Samples were removed, serially diluted, and plated onto agar plates. After overnight incubation, the colonies were counted and the percentage of
bacteria killed was determined.
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TABLE 1. Effects of media and buffers on bactericidal activities of DAPs against S. aureus ATCC 29213 and P. aeruginosa ATCC 27853
Medium or buffer mosM pH Peptide treatment(concn [mM])a
% Organisms killed at indicated incubation times:
S. aureus P. aeruginosa
30 min 1 h 2 h 4 h 30 min 1 h 2 h 4 h
Media
TSB 324 7.2 D2A21 (1) 0 0 4.6 1.7 20 34 40.6 74.7
D2A21 (5) 25.8 25 39.8 40 30.4 66 100b 100
D4E1 (1) 0 3.6 0.8 10.9 0 0 1.9 16.4
D4E1 (5) 2.3 4.2 5.3 15.8 20 56.4 75.1 54.9
NB plus 125 mM NaCl 290 7.2 D2A21 (1) 13.7 16 35.9 56.3 78.5 71.1 72.8 87
D2A21 (5) 31.1 36 52.8 73.6 100 100 100 100
D4E1 (1) 0 3.1 7 7.1 57.8 51.4 43.4 50
D4E1 (5) 38.5 42.6 56.1 46.1 100 100 100 100
adjMHB 285 7.2 D2A21 (1) 1.7 11.4 3.9 0.3 17.4 19.4 19.2 18.2
D2A21 (5) 37.3 50.4 60.4 73.1 85.4 100 100 100
D4E1 (1) 3.7 5.4 6.2 12.1 1.5 2 11.1 11
D4E1 (5) 6.7 12.2 22.2 44 36.1 50.6 60.2 60.7
MHB 297 7.2 D2A21 (1) 14.6 16.7 23.5 43.1 89.6 89.8 84 71.4
D2A21 (5) 47.9 52.1 74.5 77.6 100 100 100 100
D4E1 (1) 10.4 16.7 7.8 19 12.2 18.1 35.3 48.5
D4E1 (5) 43.8 45.8 68.6 86.2 29.9 28.8 53.1 73.2
Modified RPMI 285 7.2 D2A21 (1) 30.5 43.3 62.4 100 100 100 100 100
D2A21 (5) 84.9 85.2 100 100 100 100 100 100
D4E1 (1) 9.7 9.7 11.9 19 46.4 29.5 42.6 50.3
D4E1 (5) 49.7 75.4 100 100 68.1 100 100 100
Buffers
PBS 312 7.2 D2A21 (1) 4.7 9.3 12.6 37.5 100 100 100 100
D2A21 (5) 26.3 34.4 64 100 100 100 100 100
D4E1 (1) 1.1 0 11.8 74.8 46.6 57.6 70.7 71.9
D4E1 (5) 9 11.1 83.6 100 100 100 100 100
Tris-NaCl buffer 276 7.2 D2A21 (1) 89.2 75.6 100 100 100 100 100 100
D2A21 (5) 100 100 100 100 100 100 100 100
D4E1 (1) 11.4 19 30.7 41.6 6.9 40.7 50.7 55.4
D4E1 (5) 83.4 100 100 100 43.3 100 100 100
Tris-NaCl buffer 285 8.4 D2A21 (1) 100 100 100 100 100 100 100 100
D2A21 (5) 100 100 100 100 100 100 100 100
D4E1 (1) 100 100 100 100 100 100 100 100
D4E1 (5) 100 100 100 100 100 100 100 100
Citrate-phosphate buffer 309 7 D2A21 (1) 28.3 31 36.1 47.1 82.3 100 100 100
D2A21 (5) 26.1 77.6 100 100 100 100 100 100
D4E1 (1) 6.9 8.8 10.4 22.7 46.4 61.9 63.3 59.6
D4E1 (5) 54.3 59.5 62.2 65.2 63.3 69.7 70 85.3
Citrate-phosphate buffer 298 5 D2A21 (1) 5.2 2.3 1.3 23.1 86.8 100 100 100
D2A21 (5) 20.1 19.3 15.8 23.1 100 100 100 100
D4E1 (1) 5.9 3.8 1.1 22.7 100 100 100 100
D4E1 (5) 88.7 100 100 100 100 100 100 100
Saline 281 5.6 D2A21 (1) 30.5 32.5 42.3 57.7 100 100 100 100
D2A21 (5) 71.2 62 62.3 79.8 100 100 100 100
D4E1 (1) 13.1 59.8 100 100 17 34.8 57.1 79.6
D4E1 (5) 100 100 100 100 57.4 67.4 83.7 100
Phosphate buffer 309 7.2 D2A21 (1) 10.8 10 16.5 15.4 100 100 100 100
D2A21 (5) 28.7 52 41.6 67.7 100 100 100 100
D4E1 (1) 0 0 1.4 0 39.1 38.8 39.8 63.6
D4E1 (5) 12.4 18.3 32.9 42.5 74.2 100 100 100
a Concentrations of 1 and 5 mM D2A21 correspond to 4.3 and 21.5 mg/ml, respectively, and concentrations of 1 and 5 mM D4E1 correspond to 2.8 and 14 mg/ml,
respectively.
b Killing of $99.9% of the final inoculum was defined as 100%.
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occurring at 1 h. Furthermore, no growth of either species was
detected at 24 h after incubation with the peptides.
In TSB, NB, MHB, and adjMHB, the peptides were less
active against staphylococci. The highest reduction in staphy-
lococcal counts was seen in MHB for both peptides at a con-
centration of 5 mM; however, total killing did not occur. In
contrast, P. aeruginosa was killed by 5 mM D2A21 within 0.5 to
2 h in all four media tested and by 5 mM D4E1 within 30 min
in NB (Table 1).
In the neutral buffers, D2A21 was highly active against
P. aeruginosa, as indicated in Table 1. One micromolar D2A21
killed all organisms within 30 to 60 min. D4E1 at the same
concentration was less active, killing only up to 71.9% of all
Pseudomonas organisms after an incubation of 4 h. Both pep-
tides killed P. aeruginosa more effectively than they killed
S. aureus. Total killing of S. aureus by both peptides at 5 mM
occurred in Tris-NaCl buffer and PBS. A low level of activity
was observed in phosphate buffer. Only 67.7 and 42.5% of
staphylococci were killed by 5 mM D2A21 and D4E1, respec-
tively.
As shown in Table 1, the potencies of the peptides increased
as the pH was increased from neutral to alkaline in Tris-HCl
buffer. Both D2A21 and D4E1 at 1 mM concentrations killed
S. aureus and P. aeruginosa within 30 min at pH 8.4. In contrast,
at pH 7.2, a 2-h incubation with 1 mM D2A21 was required to
kill all organisms. Only 41.6% of the organisms were killed
after an incubation period of 4 h. Interestingly, D4E1 seemed
to become more active at pHs below the neutral range. In
citrate-phosphate buffer at pH 5.0, total killing of P. aeruginosa
and S. aureus by 5 mM D4E1 occurred within 0.5 and 1 h,
respectively, whereas in neutral citrate-phosphate buffer only
85.3% of Pseudomonas bacteria and 65.2% of staphylococci
bacteria were killed. In contrast, the antistaphylococcal activity
of D2A21 was reduced in citrate-phosphate buffer at pH 5.0.
Only 23.1% of staphylococci were killed by 5 mM D2A21,
whereas 100% of staphylococci were killed in NB. However,
the activity of D2A21 against P. aeruginosa was not affected by
the change in pH. In unbuffered saline, the antistaphylococcal
activity of D2A21 was slightly improved compared to the ac-
tivity in acidic citrate-phosphate buffer. However, the activity
of D4E1 against S. aureus but not against P. aeruginosa in-
creased significantly. Within 2 h all staphylococci were killed by
1 mM D4E1, whereas a 4-h incubation period was required to
kill all P. aeruginosa bacteria with 5 mM D4E1. Unbuffered
saline was the only environment in which S. aureus was more
susceptible to D4E1 than P. aeruginosa.
Antibacterial activities of D4E1 and D2A21 against multi-
drug-resistant pathogens. The MIC data for both peptides and
for each strain are shown in Fig. 3. D2A21 was slightly more
active than D4E1 against MRSA and multidrug-resistant
P. aeruginosa. The D2A21 MICs for MRSA ranged between
0.25 and 4 mg/ml, and those for multidrug-resistant P. aerugi-
nosa ranged between 0.125 and 4 mg/ml. The MICs at which
50% of strains are inhibited (MIC50s) for both species were 1
mg/ml. The D4E1 MICs for all MRSA and multidrug-resistant
P. aeruginosa strains tested ranged between 0.5 and 4 mg/ml,
with an MIC50 of 2 mg/ml.
The peptides were less active against S. maltophilia and
B. cepacia. The 16 isolates of S. maltophilia showed various
levels of sensitivity, with MICs ranging between 0.5 and 16
mg/ml for D2A21 (MIC50, 2 mg/ml) and 1 to 32 mg/ml for D4E1
(MIC50, 4 mg/ml). The B. cepacia isolates were much less
sensitive (D2A21 and D4E1 MICs, 32 and $64 mg/ml, respec-
tively).
Comparison of activities of DAPs with that of the naturally
occurring peptide TAP. As shown in Table 2, DAPs have
higher potencies than the naturally occurring peptide TAP
against the clinical bacterial isolates tested. The MICs of TAP
ranged between 32 and $64 mg/ml for P. aeruginosa and
MRSA, whereas the MICs of DAPs were #4 mg/ml.
Effect of osmolarity on activities of DAPs. NB has a much
lower osmolarity, ionic strength, and concentration of sodium
FIG. 3. Determination of MICs of DAPs for multidrug-resistant pathogens
from patients with CF. MICs were determined by the broth microdilution tech-
nique.
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and chloride. However, increasing the unusually low concen-
tration of NaCl in NB to the levels in isotonic and hypertonic
NB did not affect the activity of D2A21 or TAP. The D2A21
MICs in the three media with various osmolarities did not
differ more than 1 dilution interval from each other. The MICs
for only two MRSA strains exhibited twofold increases when
the strains were tested in hypertonic NB (Table 3). The MICs
of TAP were $64 mg/ml in all three media tested (data not
shown).
DISCUSSION
DAPs are synthetic peptides which are similar to naturally
occurring peptides (1, 2, 11, 12). They show antimicrobial ac-
tivity against a wide spectrum of bacteria. Although the modes
of action of these peptides are not fully understood, it is be-
lieved that peptide-lipid interactions rather than receptor-me-
diated recognition processes play a major role in their function.
Thus, it may be more difficult for bacteria to develop resistance
to these peptides than to existing antibacterial agents.
Optimal in vitro conditions for susceptibility testing of cat-
ionic peptides have not yet been established. Since these pep-
tides are highly charged, protocols such as those used for
presently available antibiotics may not be applicable. For ex-
ample, DAPs loose their antibacterial activity when they are
incorporated in agar (7), perhaps due to extensive peptide
binding to complex carbohydrates found in agar. It is also
reported that the activities of synthetic peptides of lysosomal
cathepsin G against P. aeruginosa is inhibited by calcium and
magnesium (22), whereas the opposite is true for aminoglyco-
sides, which require specific concentrations of Ca21 (20 to 25
mg/liter) and Mg21 (10 to 12.5 mg/liter) to demonstrate opti-
mal antipseudomonal activity (17). We therefore investigated
the effects of several different media on the antibacterial ac-
tivities of DAPs. Modified RPMI was the medium in which the
peptides were most active. In TSB, NB, MHB, and adjMHB,
the peptides were less active. This decrease in activity could be
due to peptide binding to complex carbohydrates such as
starch or to proteins or could be due to interference of cations
with the DAPs. An interference of cations with MSI-78, an
analog of the frog skin antibiotic magainin, was recently re-
ported (13). We also observed a decrease in the antibacterial
activities of both peptides when they were tested in cation-
adjusted MHB. Further studies are planned to determine
which medium components affect the activities of the peptides.
That pH has an effect on DAPs is demonstrated by the increase
in peptide activity in Tris-HCl buffer seen at pH 8.4 compared
to that seen at pH 7, as well as by the increased activity of
D4E1 in acidic buffers.
However, under optimal conditions as defined by these stud-
ies, DAPs have been shown to be highly potent against multi-
drug-resistant and mucoid forms of P. aeruginosa and MRSA.
Less activity was seen against S. maltophilia and B. cepacia.
Although the two extensively tested peptides D2A21 and
D4E1 did not show activity against B. cepacia isolates, D2A22,
TABLE 2. Activities of DAPs compared with that of




ATCC 27853 2 4 64
PAE-2 1 1 16
PAE-5 1 1 64
PAE-7 1 1 64
PAE-8 2 2 64
PAE-9 1 1 64
PAE-10 1 2 64
PAE-11 0.5 1 64
PAE-12 1 1 64
PAE-26 2 2 $64
PAE-30 1 2 $64
ATCC 29213 2 4 64
MRSA-1 2 2 32
MRSA-2 1 2 $64
MRSA-4 1 1 64
MRSA-5 1 2 64
MRSA-6 1 2 64
MRSA-23 1 2 $64
MRSA-24 1 4 $64
MRSA-29 1 2 64
MRSA-32 1 2 $64
MRSA-33 2 2 $64
SM-1 1 4 $64
SM-4 1 1 $64
SM-6 2 8 $64
SM-12 8 16 $64
SM-16 4 8 $64
BC-1 $64 $64 $64
BC-8 $64 $64 $64
BC-10 $64 $64 $64
BC-11 $64 $64 $64
BC-12 $64 $64 $64
a PAE, P. aeruginosa; SM, S. maltophilia; BC, B. cepacia.
TABLE 3. Effect of osmolarity on MICs of D2A21 in NB for
multidrug-resistant pathogens from patients with CF
Isolatea
MIC (mg/ml) of D2A21 in NB at
the following osmolarity:
56 mosM 290 mosM 405 mosM
ATCC 27853 4 4 4
PAE-2 2 #1 #1
PAE-5 2 2 2
PAE-7 #1 #1 #1
PAE-8 4 4 4
PAE-9 4 2 2
PAE-10 #1 #1 #1
PAE-11 #1 #1 #1
PAE-12 #1 #1 #1
PAE-26 4 2 4
PAE-30 #1 #1 #1
ATCC 29213 8 4 64
MRSA-1 2 2 4
MRSA-2 4 4 8
MRSA-4 4 8 8
MRSA-5 4 8 8
MRSA-6 4 8 16
MRSA-23 4 4 16
MRSA-24 2 4 4
MRSA-29 2 4 4
MRSA-32 4 4 8
MRSA-33 4 4 8
SM-1 4 2 4
SM-4 #1 #1 #1
SM-6 16 16 16
SM-12 8 16 16
SM-16 8 16 16
BC-1 16 32 16
BC-8 $64 $64 $64
BC-10 $64 $64 $64
BC-11 $64 $64 $64
BC-12 $64 $64 $64
a PAE, P. aeruginosa; SM, S. maltophilia; BC, B. cepacia.
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a peptide with less activity against S. aureus and P. aeruginosa,
showed a twofold increase in activity (20). These data are
promising, and on the basis of these results Demegen Inc. has
developed other peptides which will be tested for their anti-
B. cepacia activities.
Unlike the DAPs, the natural occurring peptide TAP was
not active against S. aureus ATCC 29213 and P. aeruginosa
ATCC 27853 or multidrug-resistant pathogens from patients
with CF in modified RPMI. In contrast, Lawyer et al. (11)
showed that TAP in sodium phosphate buffer (pH 7.4) has
antipseudomonal activity, highlighting again the need to stan-
dardize the conditions for peptide susceptibility testing. There
are no reports regarding the activity of TAP against gram-
positive bacteria in any system.
DAPs are particularly attractive as therapeutic agents for
patients with CF because their activities do not appear to be
diminished over a wide range of osmolarities since hyper- or
hypotonic NB did not change the activities of the peptides. In
contrast, Goldman et al. (6) observed a significant loss of
activity of hBD-1 as the salt concentration increased from 50
mM to the more physiologic range of 125 mM. We increased
the NaCl concentration in NB to as high as 250 mM, and no
change in the MICs of D2A21 for P. aeruginosa and MRSA
was observed. The slight increase in the MICs of D2A21 for
two MRSA isolates may be due to their more rapid growth in
this medium.
Since aerosolized drug delivery is a strategy used in the
treatment of CF and other airway diseases, the effect of DAPs
on a culture of human airway epithelium (157 HTB; ATCC)
has been preliminarily investigated. At antibacterial concen-
trations, no toxic effects have been detected, emphasizing that
this new class of antibiotics can be used in the treatment of CF
patients. These results support the further development of
DAPs as potentially useful antistaphylococcal and antipseudo-
monal therapies.
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